Cardiovascular Inflammation - Pipeline Review, H2 2012

Global Markets Direct, July 2012, Pages: 45

Cardiovascular Inflammation – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Cardiovascular Inflammation - Pipeline Review, H2 2012', provides an overview of the Cardiovascular Inflammation therapeutic pipeline. This report provides information on the therapeutic development for Cardiovascular Inflammation, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cardiovascular Inflammation. 'Cardiovascular Inflammation - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Cardiovascular Inflammation.
- A review of the Cardiovascular Inflammation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Cardiovascular Inflammation pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Cardiovascular Inflammation.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Cardiovascular Inflammation pipeline depth and focus of Cardiovascular Inflammation therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Cardiovascular Inflammation Therapeutic Products under Development, Key Players in Cardiovascular Inflammation Therapeutics, Cardiovascular Inflammation Pipeline Overview, Cardiovascular Inflammation Pipeline, Cardiovascular Inflammation Pipeline Assessment

2
List of Tables 4
List of Figures 4
Introduction 5
REPORT COVERAGE 5
Cardiovascular Inflammation Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Cardiovascular Inflammation 7
Cardiovascular Inflammation Therapeutics under Development by Companies 9
Cardiovascular Inflammation Therapeutics under Investigation by Universities/Institutes 10
Mid Clinical Stage Products 11
Comparative Analysis 11
Early Clinical Stage Products 12
Comparative Analysis 12
Discovery and Pre-Clinical Stage Products 13
Comparative Analysis 13
Cardiovascular Inflammation Therapeutics – Products under Development by Companies 14
Cardiovascular Inflammation Therapeutics – Products under Investigation by Universities/Institutes 15
Companies Involved in Cardiovascular Inflammation Therapeutics Development 16
Teijin Pharma Limited 16
Genfit 17
Resverlogix Corp. 18
Esperion Therapeutics, Inc. 19
RNL BIO Co., Ltd. 20
Ampio Pharmaceuticals, Inc. 21
Cardiovascular Inflammation – Therapeutics Assessment 22
Assessment by Monotherapy Products 22
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Drug Profiles 27
SAVX1 - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
ETC-1002 - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Atorvastatin - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Rituxan - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Abatacept - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
NexVas Vascular Inflammation Program - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
DMI-4983 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Venilon - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Vascostem - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Cardiovascular Inflammation Therapeutics – Drug Profile Updates 39
Cardiovascular Inflammation Therapeutics – Discontinued Products 41
Cardiovascular Inflammation Therapeutics - Dormant Products 42
Cardiovascular Inflammation – Product Development Milestones 43
Featured News & Press Releases 43
Aug 25, 2011: Pluristem's PLX Cells Receives Orphan Drug Status For Treatment Of Buerger's Disease 43
Mar 24, 2011: AnGes Publishes Results Of Collategene Study In International Angiology 43
Appendix 44
Methodology 44
Coverage 44
Secondary Research 44
Primary Research 44
Expert Panel Validation 44
Contact Us 45
Disclaimer 45

List of Tables
Number of Products Under Development for Cardiovascular Inflammation, H2 2012 7
Products under Development for Cardiovascular Inflammation – Comparative Analysis, H2 2012 8
Number of Products under Development by Companies, H2 2012 9
Number of Products under Investigation by Universities/Institutes, H2 2012 10
Comparative Analysis by Mid Clinical Stage Development, H2 2012 11
Comparative Analysis by Early Clinical Stage Development, H2 2012 12
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 13
Products under Development by Companies, H2 2012 14
Products under Investigation by Universities/Institutes, H2 2012 15
Teijin Pharma Limited, H2 2012 16
Genfit, H2 2012 17
Resverlogix Corp., H2 2012 18
Esperion Therapeutics, Inc., H2 2012 19
RNL BIO Co., Ltd., H2 2012 20
Ampio Pharmaceuticals, Inc., H2 2012 21
Assessment by Monotherapy Products, H2 2012 22
Assessment by Stage and Route of Administration, H2 2012 24
Assessment by Stage and Molecule Type, H2 2012 26
Cardiovascular Inflammation Therapeutics – Drug Profile Updates 39
Cardiovascular Inflammation Therapeutics – Discontinued Products 41
Cardiovascular Inflammation Therapeutics – Dormant Products 42

List of Figures
Number of Products under Development for Cardiovascular Inflammation, H2 2012 7
Products under Development for Cardiovascular Inflammation – Comparative Analysis, H2 2012 8
Products under Development by Companies, H2 2012 9
Products under Investigation by Universities/Institutes, H2 2012 10
Mid Clinical Stage Products, H2 2012 11
Early Clinical Stage Products, H2 2012 12
Discovery and Pre-Clinical Stage Products, H2 2012 13
Assessment by Monotherapy Products, H2 2012 22
Assessment by Route of Administration, H2 2012 23
Assessment by Stage and Route of Administration, H2 2012 24
Assessment by Molecule Type, H2 2012 25
Assessment by Stage and Molecule Type, H2 2012 26

Customers who bought this item also bought

• Skin Inflammation - Pipeline Review, H2 2012
• Ocular Inflammation - Pipeline Review, H2 2012
• Acute Pain - Pipeline Review, H2 2012
• Psoriasis - Pipeline Review, H2 2012
• Atherosclerosis - Pipeline Review, H2 2012
• Smoking Cessation - Pipeline Review, H2 2012
• Autoimmune Disorders - Pipeline Review, H2 2012
• Dyslipidemia - Pipeline Review, H2 2012
• Rheumatoid Arthritis - Pipeline Review, H2 2012
• Osteoporosis - Pipeline Review, H2 2012